

Jubilant opens new Chemistry Innovation Research Centre in Greater Noida

12 November 2021 | News

To support expanded discovery chemistry and in-vitro ADME services



Bengaluru-based contract research organisation (CRO) Jubilant Biosys has announced the expansion of its facilities to support its discovery chemistry and *in-vitro* ADME (absorption, distribution, metabolism, and excretion) Service offerings.

Jubilant Biosys provides services for Turning Point Therapeutics for multiple small molecule oncology research programmes. Turning Point is a precision oncology company developing next-generation therapies that target genetic drivers of cancer.

Services for Turning Point Therapeutics will be conducted out of the newly built state-of-the-art Chemistry Innovation Research Center (CIRC) in Greater Noida.

The CIRC has an initial capacity of 500 full-time equivalents (FTEs) enabling higher operational performance for discovery chemistry services and also rapid turn-around of *in-vitro* ADME data for client projects.